YUNKANG GROUP(02325.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
YUNKANG GROUP
02325.HK
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests; and genetic reproduction and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases.
52.19 B
02325.HKMarket value -Rank by Market Cap -/-

Financial Score

15/01/2026 Update
D
Health Care ServicesIndustry
Industry Ranking23/28
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-47.83%E
    • Profit Margin-111.74%E
    • Gross Margin33.96%C
  • Growth ScoreE
    • Revenue YoY-18.68%E
    • Net Profit YoY-160.55%E
    • Total Assets YoY-23.41%E
    • Net Assets YoY-41.69%E
  • Cash ScoreD
    • Cash Flow Margin-89.49%D
    • OCF YoY-18.68%E
  • Operating ScoreD
    • Turnover0.18D
  • Debt ScoreD
    • Gearing Ratio63.98%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Yunkang Group Signs New Property Lease Agreement in Guangzhou

    Yunkang Group Ltd. has signed a new property lease agreement for premises located at No. 1 and No. 2 Buildings, No. 6 Lizhishan Road, Science City, Guangzhou. The agreement involves a connected transaction with Guangzhou Daan and Da An Gene, including ongoing service fees related to the lease. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

    Reuters·
    HK
    02325
    -3.00%
    Reuters·
    HK
    02325
    -3.00%

    Yunkang Group Announces Change in Board Lot Size

    Yunkang Group Limited announced a change in board lot size for shares on the Hong Kong Stock Exchange, effective January 2, 2026, increasing from 500 to 3,000 shares. This aims to reduce transaction and registration costs without affecting shareholder rights. The company is also exploring future fundraising opportunities. The latest analyst rating is Hold with a HK$1.00 price target.

    Tip Ranks·
    HK
    02325
    -3.00%
    Tip Ranks·
    HK
    02325
    -3.00%

    Hong Kong Stock Movement: YUNKANG GROUP up 15.97%

    YUNKANG GROUP rose 15.97%; Health Road rose 0.13%, with a transaction amount of HKD 4.45 million; Gu Sheng Tang fell 0.74%, with a transaction amount of HKD 3.96 million; Jinxin Fertility had a transaction amount of HKD 3.47 million; Global Medical rose 0.51%, with a market value of HKD 11.3 billion

    HK Stock Movers Tracker·
    HK
    02325
    -3.00%
    HK Stock Movers Tracker·
    HK
    02325
    -3.00%

    Yunkang Group Ltd. Announces Relocation of Head Office to Guangzhou

    Yunkang Group Ltd. has announced the relocation of its head office to Guangzhou, effective September 1, 2025. The new address will be No. 6, Lizhi Shan Road, Science City, Huangpu District, Guangdong Province. The announcement was made by the company's Board, chaired by Mr. Zhang Yong.

    Reuters·
    HK
    02325
    -3.00%
    Reuters·
    HK
    02325
    -3.00%

    YUNKANG GROUP announced its interim results, with a loss attributable to owners of HKD 55.34 million, a year-on-year narrowing of 56.1%

    YUNKANG GROUP announced its mid-term results for 2025, with revenue of approximately 313 million yuan, a year-on-year decrease of 17.6%; the loss attributable to shareholders was 55.34 million yuan, a year-on-year narrowing of 56.1%. The reduction in loss was mainly due to improved operational management capabilities, strengthened cost control, and a decrease in sales management expenses. Revenue from diagnostic outsourcing services was 118.5 million yuan, a year-on-year decrease of 34.0%

    Zhitong·
    HK
    02325
    -3.00%
    Zhitong·
    HK
    02325
    -3.00%
    © 2026 Longbridge｜Disclaimer